- Home
- HOWL vs OTLK Comparison
HOWL vs OTLK Comparison
Compare HOWL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- OTLK
- Stock Information
- Founded
- HOWL 2017
- OTLK 2010
- Country
- HOWL United States
- OTLK United States
- Employees
- HOWL N/A
- OTLK N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOWL Health Care
- OTLK Health Care
- Exchange
- HOWL Nasdaq
- OTLK Nasdaq
- Market Cap
- HOWL 47.1M
- OTLK 48.3M
- IPO Year
- HOWL 2021
- OTLK 2016
- Fundamental
- Price
- HOWL $1.33
- OTLK $2.34
- Analyst Decision
- HOWL Strong Buy
- OTLK Strong Buy
- Analyst Count
- HOWL 3
- OTLK 5
- Target Price
- HOWL $8.33
- OTLK $9.60
- AVG Volume (30 Days)
- HOWL 199.3K
- OTLK 1.1M
- Earning Date
- HOWL 08-14-2025
- OTLK 08-14-2025
- Dividend Yield
- HOWL N/A
- OTLK N/A
- EPS Growth
- HOWL N/A
- OTLK N/A
- EPS
- HOWL N/A
- OTLK N/A
- Revenue
- HOWL N/A
- OTLK $1,505,322.00
- Revenue This Year
- HOWL N/A
- OTLK N/A
- Revenue Next Year
- HOWL N/A
- OTLK $407.74
- P/E Ratio
- HOWL N/A
- OTLK N/A
- Revenue Growth
- HOWL N/A
- OTLK N/A
- 52 Week Low
- HOWL $0.60
- OTLK $0.87
- 52 Week High
- HOWL $4.18
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- HOWL 58.20
- OTLK 63.83
- Support Level
- HOWL $1.12
- OTLK $1.95
- Resistance Level
- HOWL $1.29
- OTLK $2.14
- Average True Range (ATR)
- HOWL 0.08
- OTLK 0.17
- MACD
- HOWL 0.01
- OTLK 0.03
- Stochastic Oscillator
- HOWL 75.00
- OTLK 77.62
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.